We are proud and congratulate our portfolio company Versantis on its exit. French buyer GENFIT, a late-stage biopharmaceutical company, aims to strengthen its position as a leader in acute-on-chronic liver failure (ACLF) through Versantis’ strong pipeline of a Phase 2 ready program based on first-in-class scavenging liposomes technology, a pediatric program focused on urea cycle disorder (UCD), and an early-stage program focused on hepatic encephalopathy (HE).
![](https://www.occident.group/wp-content/uploads/2024/03/OCCIDENT_NEWS_Versantis_Successful-Exit_2022-09-19-1.jpg)
GENFIT pays CHF 40 million upfront and an additional CHF 65 million contingent on successful clinical and regulatory milestones, as well as one-third of the net proceeds from the potential sale of a priority review voucher, if awarded by the FDA.
More information in the press release under the following Link.